Search

Aim: The aim of this report is to describe the issue of lymphomas of urological organs through the analysis of our own patients. Methods: At the Departement of Urology in Pilsen the diagnosis of malignant lymphoma occured in ten patients in the period 2010 till 2015. We performed a retrospective analysis of the diagnostic process, disease course and outcome. Histology for confirmation of the diagnosis was obtained by surgical operation or targeted biopsy. The patients were thereafter treated by immunochemotherapy R-CHOP (rituximab, cyklophoshamid, vincristine, adriamycin/doxorubicin, prednisone) or R-COP (without doxorubicin). Resluts: Most frequent were testicular lymphomas in seven patients, one case of right adrenal lymphoma, one lymphoma of peripelvic tissue of left kidney and one patient with lymphoma of the small pelvis in close contact to the urinary bladder. Six patients with testicular lymphoma and the patient with lymphoma of peripelvic tissue achieved complete remission. In one patient with testicular lymphoma and the patient with lymphoma of the small pelvis the therapy was ongoing and regression of findings were documented at the time of publication. The patient with adrenal lymphoma achieved partial remission. Conlusion: Primary or secondary urogenital lymphomas are rare urological malignancies. Nevertheless this illness should be contemplated in the differential diagnosis. The role of urologist is to provide surgical treatment and histological verification of the disease, followed by haematooncologal therapy. Early diagnosis and prompt treatment is fundamental for inducing complete remission and for long-term survival of patients with this disease. [ABSTRACT FROM AUTHOR]

The malignant lymphomas comprise a heterogeneous group of neoplastic diseases of the lymphatic system. In the WHO classification 70 different entities are subdivided. Each type of lymphoma is defined as a disease with specific clinical characteristics, as well as morphological, immunophenotypic and genetic characteristics. The indolent lymphomas include follicular lymphoma, marginal zone lymphoma, Lymphoplasmacytic lymphoma, small cell lymphocytic lymhoma/chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. Indolent lymphomas are characterized by slow growth and a chronic course of the disease. Antibody-based therapies, have significantly improved the prognosis, nevertheless there is no curative treatment. Watch and wait is still an reasonable option in asymptomatic patients. The goal of therapy has been to maintain the best quality of life, and to avoid late toxicities. The following review presents the current treatment options. [ABSTRACT FROM AUTHOR]